DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

Expert Comments:

LifeSci Capital (11/8/18)
"DURECT Corp. received a $5M milestone upon approval of Indivior's Perseris for schizophrenia with quarterly single-digit earnouts on U.S. net sales, and the company is eligible for royalties on Orient Pharma's Methydur sustained release capsules which were recently approved in Taiwan."

Francois Brisebois, Laidlaw & Company (11/8/18)
"DURECT Corp. ended Q3/18 with $38.2M of cash and equivalents. We view its recent $20M debt amendment as positive since it enables the company to delay its principal payments by 18 months (commencing June 1, 2020 versus Dec. 1, 2018), which is a significant positive with its intent to start a NASH trial as soon as H1/19."

A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm.
read more >
Permission has been obtained to distribute time-release capsules.
read more >
Company entitled to receive quarterly earn-out payments from patent agreement.
read more >
Grant Zeng, Zacks Small-Cap Research (8/6/18)
"DURECT Corp.'s total revenue for Q2/18 was $3.4M. . .as of June 30, 2018, cash and investments were $42.5M. . .we continue to be optimistic about the company's story. . .our fair value stands at $6/share solely based on the value of its DUR-928 programs." -Zacks Small-Cap Research

Ed Arce, H.C. Wainwright & Co. (8/2/18)
"DURECT Corp.'s Q2/18 earnings per share surprised on the upside due to lower-than-expected research and development and sales and marketing expenses. . .cash, cash equivalents and short-term investments were $42.5M at Q2/18E. . .we affirm our Buy."

Francois Brisebois, Laidlaw & Company (8/2/18)
"DURECT Corp. reported its Q2/18 last night after the close, again mostly in line with expectations. Bottom line came in at $0.04 versus our anticipated $0.05. . .we consider the company a development story and continue to expect two potential Phase 2a interim readouts in primary sclerosing cholangitis and alcoholic hepatitis in H2/18."

A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts.
read more >
Ed Arce, H.C. Wainwright & Co. (7/31/18)
"Recall, in September 2017, DURECT Corp. agreed to assign certain patent rights to Indivior to provide further intellectual property protection for Perseris through at least 2026. Pursuant to that agreement, the approval of Perseris triggers a $5M milestone payment to DURECT as well as single-digit royalties (we assume 4%) on U.S. net sales of Perseris, while covered by the assigned patent rights."

More Expert Comments

Experts Following This Company

Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Francois Brisebois, Healthcare Research Analyst – Laidlaw & Company
Patrick Dolezal – LifeSci Capital
Len Yaffe, Fund Manager, analyst, MD – Stoc*Doc Partners
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
Two Late Stage Pain Products Addressing Large Markets
Company Holds the WW Rights to DUR-928 and POSIMIR